Edward Chu, MD

Professor of Medicine and Pharmacology & Chemical Biology Chief, Division of Hematology-Oncology Deputy Director, University of Pittsburgh Cancer Institute

Edward Chu, MD

chue2@upmc.edu

Office:
Phone: (412) 648-6589
Fax: (412) 648-6579

Department of Medicine

Biosketch

Brown University, Providence, RI BS 06/80 Biology
Brown University, Providence, RI MMS 06/83 Pharmacology
Brown University, Providence, RI MD 06/83 Medicine
National Cancer Institute, Bethesda, MD Fellow 06/89 Medical Oncology

Dr. Chu specializes in the treatment of colorectal and GI cancers. His basic laboratory research is focused on developing novel agents that target key cellular signaling pathways critical for the growth and proliferation of colorectal cancer. His lab-based research is also focused on developing novel approaches to overcome the process of drug resistance. clinical and translational research efforts have focused on identifying novel drugs and combination regimens for colorectal cancer and other GI cancers. In particular, he has focused on developing early-phase I/II clinical trials. He also has a strong interest in integrating Chinese herbal medicine with standard cancer chemotherapy with the goal of enhancing clinical activity and reducing the toxicity associated with chemotherapy.

  1. Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA molecules incorporating 5-fluoro-2’-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013;41:4650-4659.
  2. Schmitz, JC and Chu, E. Effect of small interfering RNA 3’-end overhangs on chemosensitivity to thymidylate synthase inhibitors. Silence. 2011;2:1-6. PMID: 21247442. PMCID: PMC3035029
  3. Wu SY, Chen TM, Gmeiner WH, Chu E, Schmitz JC. Development of modified siRNA molecules incorporating 5-fluoro-2’-deoxyuridine residues to enhance cytotoxicity. Nucleic Acids Res. 2013;41:4650-4659.
  4. Liu H, Schmitz JC, Wei J, Cao S, Beumer JH, Strychor S, Cheng L, Liu M, Wang C, Chu E, and Lin X. Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis. Oncology Res. 2014;21:247-259. PMID: 24854101 PMCID: PMC4132639
  5. Wei N, Chu E, Wipf P, and Schmitz JC. Protein kinase D as a potential chemotherapeutic target for colorectal cancer. Mol Cancer Ther. 2014;13:1130-1141. PMID: 24634417 PMCID: PMC4019967
  6. Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. Chemotherapeutic Pharmacology. 2016; in press.
  7. Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Booner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. A phase I study of DMS612, a novel bifunctional alklyating agent. 16. 2014; 21: 721-729.
  8. Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Breckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clinical Colorectal Cancer. 2011; 10: 85-96.
  9. Vater LB, Donohue JM, Arnold R, White DB, Chu E, Schenker Y. What are cancer centers advertising to the public?: a content analysis. Annals of Internal Medicine. 2014; 160: 813-820.